Leronlimab API Manufacturers

General Description:

Leronlimab, identified by CAS number 674782-26-4, is a notable compound with significant therapeutic applications. Leronlimab, or PRO-140, is a human monoclonal antibody developed by CytoDyn. It was first described in the literature in 2001. This antibody binds to CCR5, which may be useful in treating HIV, cancers, and severely ill COVID-19 patients.

Indications:

This drug is primarily indicated for: Leronlimab is currently being investigated for the treatment of a number of cancers and HIV. Recently leronlimab has begun a phase II clinical trial in severely ill COVID-19 patients. Preliminary data shows a reduction in the 'cytokine storm', particularly IL-6, as well as a normalization of the CD4/CD8 T-cell ratio. These results may mitigate immune mediate injury seen in severely ill COVID-19 patients. Its use in specific medical scenarios underscores its importance in the therapeutic landscape.

Metabolism:

Leronlimab undergoes metabolic processing primarily in: Data regarding the metabolism of leronlimab is not readily available. However, as a monoclonal antibody it is expected to be degraded to smaller proteins and amino acids by proteolytic enzymes. This metabolic pathway ensures efficient processing of the drug, helping to minimize potential toxicity and side effects.

Absorption:

The absorption characteristics of Leronlimab are crucial for its therapeutic efficacy: A 162mg subcutaneous dose reaches a C_max of 6.1mg/L, with a T_max of 32 hours, and an AUC of 24.4mg\*day/L. A 324mg subcutaneous dose reaches a C_max of 13.8mg/L, with a T_max of 56 hours, and an AUC of 58.8mg\*day/L. The drug's ability to rapidly penetrate into cells ensures quick onset of action.

Half-life:

The half-life of Leronlimab is an important consideration for its dosing schedule: The half life of a 162mg subcutaneous dose is 3.4 days while the half life of a 324mg subcutaneous dose is 3.7 days. This determines the duration of action and helps in formulating effective dosing regimens.

Protein Binding:

Leronlimab exhibits a strong affinity for binding with plasma proteins: Data regarding the protein binding of leronlimab is not readily available. This property plays a key role in the drug's pharmacokinetics and distribution within the body.

Route of Elimination:

The elimination of Leronlimab from the body primarily occurs through: Data regarding the route of elimination of leronlimab is not readily available. Understanding this pathway is essential for assessing potential drug accumulation and toxicity risks.

Volume of Distribution:

Leronlimab is distributed throughout the body with a volume of distribution of: Data regarding the volume of distribution of leronlimab is not readily available. This metric indicates how extensively the drug permeates into body tissues.

Clearance:

The clearance rate of Leronlimab is a critical factor in determining its safe and effective dosage: Data regarding the clearance of leronlimab is not readily available. It reflects the efficiency with which the drug is removed from the systemic circulation.

Pharmacodynamics:

Leronlimab exerts its therapeutic effects through: Leronlimab is a humanized monoclonal antibody that binds CCR5 being investigated for it's anti-HIV, immunomodulatory, and anti-cancer effects. The drug's ability to modulate various physiological processes underscores its efficacy in treating specific conditions.

Mechanism of Action:

Leronlimab functions by: CCR5 is a helical protein with multiple extracellular regions with adjacent G proteins. When a chemokine binds CCR5, the Gαβγ trimer phosphorylates GDP to GTP and Gα dissociates. Activated Gα activates adenylate cyclase, and increasing levels of cyclic AMP activate cytosolic protein kinase A. Further downstream effects of CCR5 signalling include activation of NF-κB and IL-6, as well as effects on cell proliferation, migration, and survival. HIV enters cells expressing CD4 and a fusion coreceptor such as CCR5 and CXCR4. Leronlimab is a monoclonal antibody which binds to multiple extracellular regions of the CCR5 receptor, preventing the entry of HIV into the cell. Leronlimab's blocking of CCR5 is being investigated in cancer treatment, for it's effect on the cell cycle and immuno-modulation. Leronlimab is also being investigated as a treatment for patients severely ill with COVID-19 due to it's effects on mitigating the cytokine storm and preventing immune-mediated injury. This mechanism highlights the drug's role in inhibiting or promoting specific biological pathways, contributing to its therapeutic effects.

Toxicity:

Classification:

Leronlimab belongs to the None, classified under the direct parent group Peptides. This compound is a part of the Organic Compounds, falling under the Organic Acids superclass, and categorized within the Carboxylic Acids and Derivatives class, specifically within the Amino Acids, Peptides, and Analogues subclass.

Categories:

Leronlimab is categorized under the following therapeutic classes: Amino Acids, Peptides, and Proteins, Anti-HIV Agents, Anti-Infective Agents, Anti-Retroviral Agents, Antibodies, Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Antibodies, Viral, Antiviral Agents, Blood Proteins, Deltaretrovirus Antibodies, Experimental Unapproved Treatments for COVID-19, Globulins, HIV Fusion Inhibitors, Immunoglobulins, Immunoproteins, Proteins, Receptors, CCR5, Serum Globulins, Viral Fusion Protein Inhibitors. These classifications highlight the drug's diverse therapeutic applications and its importance in treating various conditions.